語(yǔ)言：英文

 

　　時(shí)間：2023年9月6日

 

　　地點(diǎn)：學(xué)術(shù)會(huì)議區(qū)W201

 

　　邀請(qǐng)全球知名科學(xué)家介紹DNA存儲(chǔ)、納米毒理學(xué)等前沿科學(xué)技術(shù)，分享球差電鏡、微型化雙光子顯微鏡等高端儀器的研究進(jìn)展，同時(shí)就質(zhì)譜法和核磁共振法等研究生物大分子結(jié)構(gòu)及功能、新型分離介質(zhì)制備及蛋白藥物、疫苗純化等最新應(yīng)用進(jìn)行探討和展望。

 

　　Paul Westerhoff

 

　　報(bào)告題

 

　　目：Analytical Strategies to Assess PFAS Removal and Lifecycle Fate during Adsorption or Transformative Water Treatment Processes

 

　　報(bào)告摘要

 

　　Per- and polyfluoroalkyl substances (PFAS) occur in ground and surface water sources across the globe, and proposed drinking water regulations are driving PFAS treatment technology development and implementation. This presentation will first address current treatment technologies, which utilize adsorption (liquid to solid phase transformation), membranes (liquid to liquid separations) or transformative (oxidation or reduction) processes. Examples will be provided how treatment process efficiencies for “real waters” and how the processes challenge analytical methods. Second, the presentation addresses end-of-life for residuals (e.g., activated carbon) that contains PFAS, which will require incineration. Tracking PFAS during incineration requires unique analytical approaches to track fluorinated aqueous, gaseous and solid-phase species. Overall, the presentation will demonstrate how to match PFAS analytical strategies to PFAS drinking water treatment processes.?

 

　　個(gè)人簡(jiǎn)介

 

　　Dr. Paul Westerhoff is a Regents Professor and Fulton Chair of Environmental Engineering in the School of Sustainable Engineering and the Built Environment at Arizona State University. Since joining ASU he has held various administrative positions. After serving as the Civil and Environmental Engineering Department Chair he was the Founding Director for the School of Sustainable Engineering and the Built Environment, and served later as Associate & Vice Dean of Research in Engineering and ASU Vice Provost for Academic Programming. Dr. Westerhoff is the Deputy Director of a NSF ERC for Nanotechnology Enabled Water Treatment and co-Deputy Director of the NSF STC Science and Technologies for Phosphorus Sustainability Center. His research group addresses questions related to What pollutants exist in the environment? If they occur, do they matter? If they occur and matter, what do we do to address them? with a focus on pollutants in natural and engineered water systems. He has over 400 journal publications (H-index>100) and multiple patents. He is the recipient of the 2020 A.P. Black award, 2019 NWRI Clarke Prize, 2015 ASU Outstanding Doctoral Mentor, 2013 ARCADIS/AEESP Frontier in Research Award, and 2006 Paul L. Busch Award. He was elected to the National Academy of Engineering in 2023.

 

　　Paul Breitenbecher

 

　　報(bào)告題目：False positive, negative, and unexpected Drug Testing Results in the Urine Toxicology Laboratory |藥物測(cè)試：尿液毒理學(xué)實(shí)驗(yàn)室使用篩選法（免疫測(cè)定法）和確認(rèn)法（MS）

 

　　報(bào)告摘要

 

　　In 1995 I co-authored a short article entitled “False-positive Immunoassay Results for Urine Benzodiazepine in Patients Receiving Oxaprozin (Daypro)”. This was published when rapid urine drug screening test methods were first becoming available. The laboratory community was starting to realize that not all assays can be tested for all of the thousands of drugs, substances or endogenous compounds that may potentially cause result errors.

 

　　There are false positive, false negative and unexpected patient urine drug test results that occur in the Urine Toxicology laboratory.

 

　　How does one research these results and assist the clinician in helping to assess these results to treat their patient?

 

　　Unexpected urine drug test results can occur during any phase of the testing process; however, the most common usual results occur? during the pre- analytical or patient collection phase. During this phase patients can provide “fake” urine, take substances that can affect the testing method, or they can adulterate/dilute their urine specimen.

 

　　Depending on the screening test method used, the test method can be impacted by a variety of substances that can produce either false negative, false positive or usual results. Screening results can also be different than the confirmation results making interpretation of patient results even more confusing.

 

　　During this presentation we will review a basic screening test method and confirmation method. And discuss some of these unexpected urine drug test results.?

 

　　個(gè)人簡(jiǎn)介

 

　　Paul Breitenbecher在羅得島大學(xué)、康涅狄格大學(xué)、杜肯大學(xué)等高校進(jìn)修了研究生課程，曾在哈佛先鋒醫(yī)學(xué)中心、諾華生物醫(yī)學(xué)研究院、病理實(shí)驗(yàn)室公司（Inform Diagnostics，原名Miraca Life Sciences Inc.）等知名醫(yī)學(xué)機(jī)構(gòu)和企業(yè)的實(shí)驗(yàn)室從事管理工作?，F(xiàn)任Breiten Associates LLC公司的首席執(zhí)行官，為臨床實(shí)驗(yàn)室和CRO領(lǐng)域的科研人員提供采購(gòu)、咨詢等方面的技術(shù)支持。

 

　　Robert Wielgosz

 

　　報(bào)告題目：Certified Reference Materials for a Global Greenhouse Gas Monitoring Infrastructure?

 

　　Understanding sources and sinks of Greenhouse Gases (GHG) and the impact of policies to mitigate emissions provides a key tool for action against Climate Change. GHG emissions and uptake can be determined through measurement systems that include in situ measurement of GHG concentration at varying levels of spatial distribution. These measurements together with wind-speed measurements and numerical weather prediction and dispersion models can be used to determine spatially and time resolved GHG emissions and sinks. Maintaining a global system of such measurements, as envisaged, for example, by the WMO initiative on a coordinated global Greenhouse Gas Monitoring Infrastructure, requires close attention to quality assurance and equivalence of measurements from different sites.? Significant emissions may lead to small changes in GHG concentration, requiring highly consistent calibration standards at different measurement sites. The presentation will cover the establishment and characterization of CO2 in air standards for the measurements of concentration as well as isotope ratio, for source apportionment, that are required in GHG measurement networks. Generating the highest precision measurements of CO2 in air requires adopting metrological traceability to defined sets of primary standards, the so-called scale approach. The conversion of CO2 in air amount fraction values from one scale to another requires the scale relationships to be well known, noting that the requirement for internal consistency of standards within a scale, such as the WMO-CO2-X2019 scale, is at the 0.01 μmol/mol level, and consistency between different scales should not exceed the 0.02 μmol/mol level [1].? Certified reference materials that are needed to calibrate both in-situ based optical/laser based GHG amount faction and isotope ratio measurements as well as mass spectrometric laboratory-based measurements of isotope ratio will be described, as well as on-going comparisons to verify their equivalence. These comparisons are supporting National

 

　　個(gè)人簡(jiǎn)介

 

　　Robert Wielgosz博士是位于法國(guó)的國(guó)際計(jì)量局（BIPM）化學(xué)部的主任，其氣體計(jì)量實(shí)驗(yàn)室負(fù)責(zé)組織空氣質(zhì)量和溫室氣體標(biāo)準(zhǔn)國(guó)際比對(duì)。這些比對(duì)為由國(guó)家計(jì)量院（NMIs）和指定機(jī)構(gòu)（DIs）組成的世全球大氣監(jiān)測(cè)網(wǎng)絡(luò)提供標(biāo)準(zhǔn)支撐。他是國(guó)際計(jì)量委員會(huì)（CIPM）氣候變化和環(huán)境領(lǐng)域任務(wù)組成員，也是國(guó)際計(jì)量局-世界氣象組織（WMO）“氣候行動(dòng)中的計(jì)量”研討會(huì)指導(dǎo)委員會(huì)主席。他發(fā)表測(cè)量科學(xué)相關(guān)論文60余篇，包括世界氣象組織大氣氣體成分測(cè)量指南。他擁有劍橋大學(xué)伊曼紐爾學(xué)院（英國(guó)）的自然科學(xué)碩士學(xué)位，巴斯大學(xué)（英國(guó)）的博士學(xué)位，并在烏爾姆大學(xué)（德國(guó)）完成了皇家學(xué)會(huì)歐洲交流研究。

 

　　Oliver J. Schmitz

 

　　報(bào)告題目：Development of a New Ionization Source for Single Cell metabolome Analysis

 

　　報(bào)告摘要

 

　　Although the unrevealing of cellular heterogeneity is limiting for the understanding of complex processes in cancer research as e.g. its influence on the process of metastasising, current research still depends on bulk analysis technologies as no reliable method could be established for real single cell metabolome analysis yet.

 

　　The necessary analytical requirements that such a method for single cell metabolome analysis needs in terms of detection limit, sample amount and specificity will be discussed in detail in this presentation. Also, still unsolved problems will be addressed and put up for discussion.

 

　　Subsequently, our current work on an ion source, which should be able to destroy the cell and thus release the analytes and ionize them by means of Dielectric Barrier Discharge, will be presented. The current status of developments from the literature and from us will be briefly presented in this talk.

 

 

　　In 2009 Oliver J. Schmitz got a full professor in Analytical Chemistry at the University of Wuppertal (BUW). Between 2010 and 2012 he was the chair of the Analytical Chemistry department at BUW. Since 2013, Schmitz has been a full professor at the University of Duisburg-Essen and heads the Institute for Applied Analytical Chemistry.

 

　　2009 he cofounded the company iGenTraX UG which develops new ion sources and units to couple separation techniques with mass spectrometers. In 2011 he was one of the founding directorsof the Interdisciplinary Centre for Pure and Applied Mass Spectrometry, University of Wuppertal. Since 2013, Schmitz is also one of the chairmen of the analytica conferences in China and Vietnam and in 2018, together with Agilent Technologies, he founded the Teaching and Research Center for Separation (TRC).

 

　　The research fields of Prof. Schmitz are the development of ion sources, use and optimization of multi-dimensional LC and GC, ion mobility-mass spectrometry and coupling analytical techniques with mass spectrometers. Furthermore, he is working about origin of life and metabolomics. Prof. Schmitz was awarded the scholar-in-training award of the American Association for Cancer Research in 2003, the Gerhard-Hesse Prize for chromatography in 2013 and in the same year the Fresenius Lecturer. 2018 he was awarded with the Waksmundzki Medal Award for Analytical Chemistry of the Polish Academy of Sciences.

 

　　馬光輝

 

　　美國(guó)醫(yī)學(xué)與生物工程院（AIMBE）fellow

 

　　中國(guó)科學(xué)院過(guò)程工程研究所研究員

 

　　生化工程國(guó)家重點(diǎn)實(shí)驗(yàn)室主任

 

　　中國(guó)顆粒學(xué)會(huì)副理事長(zhǎng)

 

　　中國(guó)化學(xué)會(huì)會(huì)士

 

　　中國(guó)化工學(xué)會(huì)會(huì)士

 

　　中國(guó)微米納米技術(shù)學(xué)會(huì)會(huì)士

 

　　中國(guó)化工學(xué)會(huì)生物化工專業(yè)委員會(huì)副主任委員

 

　　中國(guó)生物工程學(xué)會(huì)生物基材料專業(yè)委員會(huì)主任委員

 

　　報(bào)告題目：新型分離介質(zhì)的制備和蛋白藥/疫苗純化應(yīng)用Preparation of Novel Microspheres for Protein / Vaccine Separation Application

 

　　Polysaccharide particles such like agarose particles have been widely used in protein separation and purification as chromatographic packing materials by biological scientists and in industry. However, the limitation of conventional agarose particles is that the separation resolution is limited due to their broad size distribution. Furthermore, the particles with large size are usually used for industrial separation and purification to avoid the increase of back-pressure, which also limit the separation resolution. On the other hand, the particulate vaccine such like virus-like particle (VLP) has attracted more and more attention, conventional agarose particles with small pore size not only limited the adsorption of VLP, but also enhanced the disassociation of VLP, resulting very low activity recovery of VLP.We have developed a novel membrane process to prepare uniform agarose particle. By this technique we can control the CV (coefficient of variation) value which representing the size distribution around 15%, and we can prepare small uniform particles with high agarose concentration. Therefore, we can use small particles instead of large particles, and increase the separation resolution and flow rate of chromatography. ?We have developed a new process to prepare giga-porous particle with pore size controllable between 100nm to 500 nm, and we found that it not only increased the loading amount of VLP, but also avoided the disassociation of VLP. This was because large pore size weakened the multi-site interaction between VLP and pore. This novel particle has been used for production of particulate vaccine instead of ultra-high speed centrifugation technique, much higher recovery was achieved.

 

　　馬光輝，中國(guó)科學(xué)院院士，美國(guó)醫(yī)學(xué)與生物工程院（AIMBE）fellow，生化工程國(guó)家重點(diǎn)實(shí)驗(yàn)室主任。國(guó)家杰出青年獲得者，基金委創(chuàng)新群體首席，中國(guó)顆粒學(xué)會(huì)副理事長(zhǎng)，中國(guó)化學(xué)會(huì)會(huì)士、中國(guó)化工學(xué)會(huì)會(huì)士、中國(guó)微米納米技術(shù)學(xué)會(huì)會(huì)士、中國(guó)化工學(xué)會(huì)生物化工專業(yè)委員會(huì)副主任委員、中國(guó)生物工程學(xué)會(huì)生物基材料專業(yè)委員會(huì)主任委員。研究方向?yàn)榫簧镂⑶蚝臀⒛业闹苽浼捌湓谏こ毯歪t(yī)學(xué)工程中的應(yīng)用，研究和開(kāi)發(fā)用于生化分離、藥物載體、免疫佐劑（疫苗遞送系統(tǒng)）、細(xì)胞培養(yǎng)微載體、酶固定化載體等創(chuàng)新產(chǎn)品。在Nat. Mater., Sci. Transl. Med., Nat. Nanotechnol., Nat. Biomed. Eng., Sci. Adv., Nat. Commun., JACS, Adv. Mater.等國(guó)際著名學(xué)術(shù)期刊上發(fā)表SCI論文500余篇。出版中英文專著12部，撰寫學(xué)術(shù)書章節(jié)22篇。中國(guó)發(fā)明專利授權(quán)81項(xiàng)，國(guó)際專利授權(quán)12項(xiàng)，專利技術(shù)和產(chǎn)品在國(guó)內(nèi)外500多家單位得到應(yīng)用。獲國(guó)家技術(shù)發(fā)明二等獎(jiǎng)、北京市科學(xué)技術(shù)一等獎(jiǎng)、中國(guó)化工學(xué)會(huì)科學(xué)技術(shù)獎(jiǎng)基礎(chǔ)研究成果獎(jiǎng)一等獎(jiǎng)、中國(guó)顆粒學(xué)會(huì)自然科學(xué)獎(jiǎng)一等獎(jiǎng)、中國(guó)石油和化學(xué)工業(yè)聯(lián)合會(huì)技術(shù)發(fā)明一等獎(jiǎng)、侯德榜化工科技創(chuàng)新獎(jiǎng)、“中國(guó)科協(xié)全國(guó)優(yōu)秀科技工作者”稱號(hào)。

 

　　程和平

 

　　北京大學(xué)未來(lái)技術(shù)學(xué)院 教授

 

　　北京大學(xué)分子醫(yī)學(xué)南京轉(zhuǎn)化研究院 院長(zhǎng)

 

　　北京大學(xué)國(guó)家生物醫(yī)學(xué)成像科學(xué)中心 主任

 

　　國(guó)家十三五重大科技設(shè)施“多模態(tài)跨尺度生物醫(yī)學(xué)成像設(shè)施” 首席科學(xué)家

 

　　報(bào)告題目：科技鑄器，開(kāi)啟腦科學(xué)研究新范式

 

　　腦科學(xué)研究包括“讀、釋、寫、仿”四個(gè)方面，是一門高度交叉的新興前沿學(xué)科。為開(kāi)發(fā)“讀、釋、寫、仿”工具，團(tuán)隊(duì)于2017年成功研發(fā)了2.2克微型化雙光子顯微鏡，實(shí)現(xiàn)了在自由行為小鼠觀察大腦神經(jīng)元活動(dòng)，開(kāi)啟腦科學(xué)研究的新范式。2021年，第二代微型化雙光子顯微鏡問(wèn)世，實(shí)現(xiàn)了三維空間中近千個(gè)神經(jīng)元的功能成像，開(kāi)啟了在自由行為動(dòng)物研究大腦神經(jīng)元結(jié)構(gòu)和功能的新范式。2023年成功研發(fā)了2.17克的微型化三光子顯微鏡，首次實(shí)現(xiàn)對(duì)自由行為中小鼠的大腦全皮層和海馬神經(jīng)元功能成像，為揭示大腦深部神經(jīng)機(jī)制提供了又一利器。為支撐中國(guó)的“腦計(jì)劃”，我們建設(shè)了“南京腦觀象臺(tái)”，由相關(guān)領(lǐng)域?qū)＜翌I(lǐng)銜，正在開(kāi)展腦科學(xué)“探索計(jì)劃”項(xiàng)目，主題涉及皮質(zhì)工作記憶、睡眠、自閉癥、抑郁癥、神經(jīng)藥理學(xué)和神經(jīng)元再生等。作為國(guó)之重器，“多模態(tài)跨尺度生物醫(yī)學(xué)成像設(shè)施”（國(guó)家十三五重大科技基礎(chǔ)設(shè)施）的建設(shè)正在如火如荼地展開(kāi)，預(yù)期于今年底投入試運(yùn)行，2024年完成國(guó)家驗(yàn)收。依托此成像大設(shè)施，已啟動(dòng)“早鳥(niǎo)項(xiàng)目”，面向全國(guó)科技界滾動(dòng)征集合作立項(xiàng)建議，計(jì)劃在未來(lái)3-5年內(nèi)發(fā)起生命科學(xué)包括腦科學(xué)領(lǐng)域的大科學(xué)計(jì)劃，充分發(fā)揮“科技航母”的戰(zhàn)略價(jià)值。大科學(xué)時(shí)代的生命科學(xué)特別需要新的工具，需要新型的研究平臺(tái)。未來(lái)，更多新工具的開(kāi)發(fā)以及新范式的探索，特別是大科學(xué)時(shí)代有組織科研的新范式，將為提升我國(guó)生物醫(yī)學(xué)研究的整體水平，尤其是原始創(chuàng)新能力，實(shí)現(xiàn)高端生物醫(yī)學(xué)儀器裝備的“中國(guó)創(chuàng)造”提供強(qiáng)有力的戰(zhàn)略支撐和保障。

 

　　個(gè)人簡(jiǎn)介

 

　　程和平院士長(zhǎng)期致力于鈣信號(hào)、線粒體生物醫(yī)學(xué)領(lǐng)域的研究，以及高端生物醫(yī)學(xué)儀器的自主創(chuàng)制。主要學(xué)術(shù)貢獻(xiàn)為 ① 發(fā)現(xiàn)細(xì)胞鈣信號(hào)基本單位—“鈣火花”（Calcium Spark），原始論文曾被譽(yù)為100多年來(lái)十篇最杰出的心肌研究論文之一；② 發(fā)現(xiàn)線粒體 “超氧炫”又稱“線粒體炫”（Mitoflash），揭示其在能量代謝、學(xué)習(xí)記憶及衰老生物學(xué)中的信號(hào)功能；③率團(tuán)隊(duì)研發(fā)2.2克微型雙光子顯微鏡，實(shí)現(xiàn)了在自由活動(dòng)小鼠觀察大腦神經(jīng)元活動(dòng)，開(kāi)啟腦科學(xué)研究的新范式。該項(xiàng)成果獲“2017年中國(guó)科學(xué)十大進(jìn)展”，并入選Nature Methods“2018年度方法”。此外，獲國(guó)際心臟學(xué)會(huì)“Research Achievement Award”(2016），國(guó)家自然科學(xué)獎(jiǎng)二等獎(jiǎng) （2017），何梁何利基金科學(xué)與技術(shù)進(jìn)步獎(jiǎng)（2020），北京大學(xué)2021年度國(guó)華杰出學(xué)者獎(jiǎng)（2021），中國(guó)專利優(yōu)秀獎(jiǎng)（2022）等。

 

　　后疫情 大健康高峰論

 

　　邀請(qǐng)相關(guān)領(lǐng)導(dǎo)解讀健康管理等宏觀政策，行業(yè)內(nèi)知名專家分享腫瘤、病毒對(duì)抗等前沿進(jìn)展以及癌癥早期篩查與診斷、標(biāo)志物檢測(cè)等內(nèi)容，炙手可熱的POCT、臨床質(zhì)譜、生物芯片等相關(guān)儀器應(yīng)用也將進(jìn)行現(xiàn)場(chǎng)展示。

 

　　闞海東　教授

 

　　復(fù)旦大學(xué)公共衛(wèi)生學(xué)院副院長(zhǎng)；

 

　　教育部長(zhǎng)江學(xué)者特聘教授；

 

　　國(guó)家環(huán)境與健康專家咨詢委員會(huì)委員；

 

　　Environmental Health Perspectives雜志副主編；

 

　　International Journal of Epidemiology雜志副主編

 

　　報(bào)告題目：“雙碳”背景下的空氣污染、氣候變化與公共衛(wèi)生

 

　　摘 要

 

　　氣候變化是21世紀(jì)人類面臨的最大健康挑戰(zhàn)，空氣污染也是全球重要的公共衛(wèi)生問(wèn)題。我國(guó)提出2030年前實(shí)現(xiàn)碳達(dá)峰、2060年前實(shí)現(xiàn)碳中和的“雙碳”目標(biāo)，不僅會(huì)對(duì)我國(guó)空氣污染和氣候狀況產(chǎn)生深遠(yuǎn)影響，也會(huì)全面影響人群健康。報(bào)告將圍繞“雙碳”目標(biāo)背景下的空氣污染、氣候變化與公共衛(wèi)生的研究現(xiàn)狀和未來(lái)趨勢(shì)展開(kāi)論述，以期為后續(xù)更好地開(kāi)展環(huán)境與健康研究提供思路和建議。

 

　　個(gè)人簡(jiǎn)介

 

　　復(fù)旦大學(xué)公共衛(wèi)生學(xué)院副院長(zhǎng)、教育部長(zhǎng)江學(xué)者特聘教授。任國(guó)家環(huán)境與健康專家咨詢委員會(huì)委員、Environmental Health Perspectives雜志副主編、International Journal of Epidemiology雜志副主編。曾獲《新英格蘭醫(yī)學(xué)雜志》年度最佳論文獎(jiǎng)、吳階平-保羅·楊森醫(yī)學(xué)藥學(xué)獎(jiǎng)、CMB杰出教授獎(jiǎng)、美國(guó)環(huán)保署科學(xué)技術(shù)成就獎(jiǎng)、上海市科技進(jìn)步一等獎(jiǎng)（1）等。

 

　　軍事科學(xué)院軍事醫(yī)學(xué)研究院生物工程研究所科技委主任；

 

　　中國(guó)生物工程學(xué)會(huì)副秘書長(zhǎng)；

 

　　中國(guó)生物工程學(xué)會(huì)醫(yī)學(xué)生物技術(shù)專業(yè)委員會(huì)主任委員；

 

　　中國(guó)分析測(cè)試協(xié)會(huì)標(biāo)記免疫分析專業(yè)委員會(huì)副主任委員

 

　　報(bào)告題目：糖代謝與腫瘤生長(zhǎng)和轉(zhuǎn)移

 

　　正常細(xì)胞在有氧時(shí)通過(guò)糖的有氧氧化獲取能量，只有在缺氧時(shí)才進(jìn)行無(wú)氧糖酵解；而腫瘤細(xì)胞無(wú)論在氧氣充足還是缺氧環(huán)境下，都表現(xiàn)為糖酵解水平顯著增強(qiáng)，而有氧氧化效率受到抑制，這種現(xiàn)象被稱為Warburg效應(yīng)或有氧糖酵解，導(dǎo)致腫瘤細(xì)胞葡萄糖攝取能力增強(qiáng)，乳酸水平升高，有利于腫瘤生長(zhǎng)和轉(zhuǎn)移。Warburg效應(yīng)被認(rèn)為是腫瘤標(biāo)志之一，靶向Warburg效應(yīng)的抗腫瘤藥物正在被開(kāi)發(fā)。轉(zhuǎn)錄因子和轉(zhuǎn)錄輔助因子在Warburg效應(yīng)調(diào)節(jié)中發(fā)揮重要作用，缺氧誘導(dǎo)因子HIF-1和癌基因c-Myc?是促進(jìn)糖酵解的轉(zhuǎn)錄因子，抑癌基因p53是抑制糖酵解、維持線粒體有氧呼吸功能的轉(zhuǎn)錄因子。我們實(shí)驗(yàn)室的工作發(fā)現(xiàn)，轉(zhuǎn)錄因子SIX1通過(guò)與組蛋白修飾酶HBO1和AIB1的相互作用調(diào)節(jié)Warburg效應(yīng)，促進(jìn)腫瘤生長(zhǎng)，腫瘤相關(guān)SIX1點(diǎn)突變進(jìn)一步促進(jìn)了腫瘤細(xì)胞的有氧糖酵解和腫瘤生長(zhǎng)。與SIX1功能相反，轉(zhuǎn)錄因子OVOL2通過(guò)募集轉(zhuǎn)錄共抑制因子NCoR和組蛋白去乙酰酶HDAC3來(lái)抑制糖酵解基因的表達(dá)，從而阻斷Warburg效應(yīng)，抑制腫瘤的生長(zhǎng)和轉(zhuǎn)移。p53通過(guò)與癌蛋白MDM2的結(jié)合抑制MDM2介導(dǎo)的OVOL2的泛素化和OVOL2的降解，從而激活OVOL2。SIX1高表達(dá)是腫瘤患者不良的預(yù)后指標(biāo)，而OVOL2高表達(dá)是腫瘤患者良好的預(yù)后指標(biāo)。我們的研究深入闡明了糖代謝與腫瘤生長(zhǎng)和轉(zhuǎn)移的關(guān)系，為腫瘤的診斷和治療提供了新的思路和候選靶標(biāo)。

 

　　個(gè)人簡(jiǎn)介

 

　　葉棋濃，軍事科學(xué)院軍事醫(yī)學(xué)研究院生物工程研究所科技委主任，研究員，博士生導(dǎo)師。國(guó)家杰出青年科學(xué)基金獲得者，享受國(guó)務(wù)院政府特殊津貼。中國(guó)生物工程學(xué)會(huì)副秘書長(zhǎng)、中國(guó)生物工程學(xué)會(huì)醫(yī)學(xué)生物技術(shù)專業(yè)委員會(huì)主任委員、中國(guó)分析測(cè)試協(xié)會(huì)標(biāo)記免疫分析專業(yè)委員會(huì)副主任委員。Frontiers in Cell and Developmental Biology和Frontiers in Oncology雜志副編輯。1989年畢業(yè)于南開(kāi)大學(xué)生物系，分別于1992年和1995年獲得軍事醫(yī)學(xué)科學(xué)院分子遺傳專業(yè)碩士和博士學(xué)位，1998年10月至2002年2月在美國(guó)弗吉尼亞大學(xué)醫(yī)學(xué)院做博士后研究工作。主要從事腫瘤發(fā)生、侵襲、轉(zhuǎn)移、耐藥相關(guān)基因功能及機(jī)制研究，發(fā)現(xiàn)了一批新的調(diào)控重要信號(hào)轉(zhuǎn)導(dǎo)通路的基因和非編碼RNA，為腫瘤的診斷和治療提供候選靶標(biāo)。以通訊作者在Cancer Cell、Nature Communications、Science Advances、JCI、Advanced Science、Science Bulletin、STTT等SCI雜志上發(fā)表論文80余篇。獲北京市科學(xué)技術(shù)一等獎(jiǎng)1項(xiàng)，軍隊(duì)科技進(jìn)步二等獎(jiǎng)1項(xiàng)。

 

　　宋海波

 

　　全國(guó)衛(wèi)生產(chǎn)業(yè)企業(yè)管理協(xié)會(huì)副會(huì)長(zhǎng)；

 

　　全國(guó)衛(wèi)生產(chǎn)業(yè)企業(yè)管理協(xié)會(huì)醫(yī)學(xué)檢驗(yàn)產(chǎn)業(yè)分會(huì)會(huì)長(zhǎng)；

 

　　中國(guó)分析測(cè)試協(xié)會(huì)標(biāo)記免疫分析專業(yè)委員會(huì)副主任委員；

 

　　全國(guó)衛(wèi)生產(chǎn)業(yè)企業(yè)管理協(xié)會(huì)實(shí)驗(yàn)醫(yī)學(xué)分會(huì)副主任委員兼秘書長(zhǎng)；

 

　　全國(guó)醫(yī)用臨床檢驗(yàn)實(shí)驗(yàn)室和體外診斷系統(tǒng)標(biāo)準(zhǔn)化技術(shù)委員會(huì)常務(wù)委員；

 

　　上海市實(shí)驗(yàn)醫(yī)學(xué)研究院副院長(zhǎng)

 

　　報(bào)告題目：后疫情時(shí)代檢驗(yàn)醫(yī)學(xué)產(chǎn)業(yè)發(fā)展及挑戰(zhàn)

 

　　宋海波，主任技師、教授。1980年2月從事檢驗(yàn)醫(yī)學(xué)工作，83年師從軍事醫(yī)學(xué)科學(xué)院葛忠良教授從事造血干細(xì)胞研究工作。84年在安徽省立醫(yī)院血液病室從事實(shí)驗(yàn)血液學(xué)工作，86年從事體外診斷試劑工作任安徽省立醫(yī)院試劑部主任。1994年任安徽省臨床檢驗(yàn)中心副主任、兼任安徽省第三、四屆微免學(xué)會(huì)副主委、安徽省衛(wèi)生廳輸血質(zhì)量管理委員會(huì)委員副秘書長(zhǎng)，安徽省輸血協(xié)會(huì)常務(wù)理事，安徽省衛(wèi)生廳亞光醫(yī)學(xué)科技開(kāi)發(fā)總公司副總經(jīng)理兼合肥振安醫(yī)學(xué)檢驗(yàn)用品公司總經(jīng)理。2004年宋海波創(chuàng)辦了檢驗(yàn)醫(yī)學(xué)暨輸血儀器試劑博覽會(huì)，該會(huì)目前已成為全世界規(guī)模最大的體外診斷博覽會(huì)。其主編的由上?？萍汲霭嫔绯霭姘l(fā)行的《中國(guó)體外診斷產(chǎn)業(yè)發(fā)展藍(lán)皮書》（每年一卷），至今已連續(xù)出版了五卷，該書真實(shí)地記錄了改革開(kāi)放40多年來(lái)我國(guó)體外診斷產(chǎn)業(yè)發(fā)展的歷程、事件、儀器試劑研究現(xiàn)狀與進(jìn)展、行業(yè)狀態(tài)、產(chǎn)業(yè)數(shù)據(jù)、技術(shù)轉(zhuǎn)化、新技術(shù)應(yīng)用等，該書填補(bǔ)了中國(guó)體外診斷產(chǎn)業(yè)和出版界的空白。他還擔(dān)任數(shù)本期刊的常務(wù)編委和幾所高校的客座教授。

 

　　邱玲

 

　　北京協(xié)和醫(yī)院檢驗(yàn)科副主任

 

　　北京協(xié)和醫(yī)學(xué)院臨床檢驗(yàn)診斷學(xué)系副主任

 

　　報(bào)告題目：臨床質(zhì)譜助力精準(zhǔn)診療和學(xué)科發(fā)展

 

　　報(bào)告將從臨床質(zhì)譜發(fā)展史、醫(yī)療機(jī)構(gòu)質(zhì)譜平臺(tái)設(shè)置、儀器配置等角度入手，以北京協(xié)和醫(yī)院臨床質(zhì)譜平臺(tái)發(fā)展為例，介紹以臨床需求為導(dǎo)向開(kāi)展質(zhì)譜臨床項(xiàng)目，從多角度滿足臨床疑難、罕見(jiàn)病診療需求的探索。同時(shí)將介紹臨床質(zhì)譜從小分子向大分子、從“峰”向“空間”、從“多指標(biāo)”向“多組學(xué)”的轉(zhuǎn)換，為質(zhì)譜技術(shù)落地臨床提供可行性建議。

 

　　個(gè)人簡(jiǎn)介

 

　　邱玲，研究員,教授，博士/博士后導(dǎo)師，北京協(xié)和醫(yī)院檢驗(yàn)科副主任，北京協(xié)和醫(yī)學(xué)院臨床檢驗(yàn)診斷學(xué)系副主任?，F(xiàn)擔(dān)任中國(guó)老年醫(yī)學(xué)學(xué)會(huì)檢驗(yàn)醫(yī)學(xué)分會(huì)副會(huì)長(zhǎng)、中華醫(yī)學(xué)會(huì)檢驗(yàn)分會(huì)生化學(xué)組委員、北京檢驗(yàn)學(xué)會(huì)副主委、CNAS?醫(yī)學(xué)實(shí)驗(yàn)室認(rèn)可主任評(píng)審員、國(guó)家衛(wèi)生標(biāo)準(zhǔn)委員臨床檢驗(yàn)標(biāo)準(zhǔn)專業(yè)委員會(huì)委員等社會(huì)職務(wù)。主持國(guó)家自然科學(xué)基金、首發(fā)基金重點(diǎn)項(xiàng)目、科技部重點(diǎn)支撐子項(xiàng)目等共17項(xiàng)。以第一作者、通訊作者發(fā)表SCI論著90余篇（IF>300分）、核心期刊論著100余篇。獲省級(jí)科技進(jìn)步二、三等獎(jiǎng)各一項(xiàng)，授權(quán)發(fā)明專利11項(xiàng)（歐洲專利2項(xiàng)），牽頭體外診斷產(chǎn)品注冊(cè)試驗(yàn)60余項(xiàng)。全國(guó)三八紅旗手，全國(guó)民族團(tuán)結(jié)進(jìn)步先進(jìn)個(gè)人，2021中國(guó)最美醫(yī)生。

 

　　康熙雄

 

 

　　健康中國(guó)建設(shè)的十五個(gè)專項(xiàng)行動(dòng)大大推動(dòng)了走健康強(qiáng)國(guó)之步伐，同時(shí)也對(duì)我們提出要達(dá)到精準(zhǔn)健康必須要具備個(gè)體化健康評(píng)價(jià)能力，而這種能力必須包括生命全程每階段的健康評(píng)價(jià)能力。至今，人類在疫情和疾病的泛濫之下尚未來(lái)得及認(rèn)真考慮全生命周期健康評(píng)價(jià)體系的建立。隨著分析科學(xué)的迅速發(fā)展，大量的人體生理信息的釆集變?yōu)楝F(xiàn)實(shí)。這些可釆集的生理化學(xué)生命信息對(duì)評(píng)價(jià)個(gè)體的發(fā)生、生長(zhǎng)、成熟、衰老和走向臨終的健康狀態(tài)具有重要的作用。如何建立完善的可釆集生命全周期的分析系統(tǒng)，將其變?yōu)榭梢宰鳛槌Ｒ?guī)應(yīng)用的產(chǎn)品，再建立把釆集的數(shù)據(jù)作為大數(shù)據(jù)的底座用成熟算法計(jì)算的模型后完善數(shù)字化健康孿生人已成為重要健康強(qiáng)國(guó)的手段和目標(biāo)。

 

　　個(gè)人簡(jiǎn)介

 

　　康熙雄教授，1978年8月畢業(yè)于白求恩醫(yī)科大學(xué)醫(yī)療系，入職白求恩醫(yī)大三院；1993年8月任白求恩醫(yī)科大學(xué)教授、主任醫(yī)師；1997年4月-2001年7月在在東京大學(xué)醫(yī)學(xué)科學(xué)研究所任研究員；2001年8月任職于首都醫(yī)科大學(xué)北京天壇醫(yī)院實(shí)驗(yàn)診斷中心；2018年8月兼任北京航天航空大學(xué)生物與醫(yī)學(xué)工程學(xué)院博士生導(dǎo)師。